<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863560</url>
  </required_header>
  <id_info>
    <org_study_id>PF-CRA-2073</org_study_id>
    <secondary_id>286383</secondary_id>
    <secondary_id>20/LO/1036</secondary_id>
    <nct_id>NCT04863560</nct_id>
  </id_info>
  <brief_title>Brain Activity During Gait in Parkinson's</brief_title>
  <acronym>BARC-PD</acronym>
  <official_title>Brain Activity Response to Cues During Gait in Parkinson's</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parkinson's Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northumbria Healthcare NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lay Summary:&#xD;
&#xD;
      Walking problems, such as slow and short steps, are very common in Parkinson's disease and&#xD;
      lead to increased falls risk, as well as reduced mobility and quality of life. Walking issues&#xD;
      are difficult to treat as medication interventions do not restore walking ability in people&#xD;
      with Parkinson's, therefore physiotherapy approaches are used to help improve walking.&#xD;
      Various physiotherapy strategies have been used, such as internal (thinking about bigger&#xD;
      steps) or external prompts. External prompts include auditory (a metronome beat to step in&#xD;
      time to), visual (lines to step over on the floor) and tactile (metronome-like vibration to&#xD;
      step with) prompts that are very commonly used to improve walking in Parkinson's. However,&#xD;
      the reason why walking improves in people with Parkinson's with these physiotherapy&#xD;
      strategies is unknown, which has led to not all patients benefiting and only short-term&#xD;
      walking improvements being seen.&#xD;
&#xD;
      The main issues are that it is unclear if these various internal or external prompt&#xD;
      strategies are effective with the progression of Parkinson's disease, and it is unknown which&#xD;
      type of strategy is most effective at different disease stages or with more severe walking&#xD;
      impairment, such as freezing (the inability to progress walking for short periods despite&#xD;
      wanting to do so). Being able to use specific brain regions to pay attention to different&#xD;
      internal or external prompts has been suggested to be the reason why people with Parkinson's&#xD;
      can overcome their walking problems, but this has not been tested. Therefore, this study will&#xD;
      use state-of-the-art digital technology to measure walking and brain activity changes with&#xD;
      different internal and external prompts. The investigators think that the walking improvement&#xD;
      with different prompt strategies relies on the ability to activate specific brain regions,&#xD;
      and that brain region activity in response to internal or external prompts will change at&#xD;
      different stages of Parkinson's disease.&#xD;
&#xD;
      Ultimately, understanding the reasons why people benefit from these physiotherapy strategies&#xD;
      and who benefits most from specific strategies will enable clinicians to provide more timely&#xD;
      and efficient treatment for people with Parkinson's, and to develop more effective strategies&#xD;
      to further improve walking.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cortical oxygenated hemoglobin (HbO2) signal during walking</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in cortical oxygenated hemoglobin (HbO2) measured while walking with cueing, which will be quantified with a wireless functional near infrared spectroscopy (fNIRS) system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cortical power spectral densities during walking</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in cortical power spectral densities of EEG signals from cortex with cueing, which will be quantified with a mobile electroencephalography (EEG) system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Stride Length (m)</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in stride length with cueing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gait Speed (m/s)</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in speed of walking with cueing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Stride Time (s)</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in time taken to complete a stride when walking with cues</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gait Variability (SD)</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Change in variability (standard deviation; SD) of gait when walking with cues</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Hoehn &amp; Yahr stage I (H&amp;YI)</arm_group_label>
    <description>- 20 Hoehn &amp; Yahr stage I (early disease, minimal symptoms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hoehn &amp; Yahr stage II (H&amp;YII)</arm_group_label>
    <description>- 30 Hoehn &amp; Yahr stage II (mild disease, no balance issues)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hoehn &amp; Yahr stage III (H&amp;YIII)</arm_group_label>
    <description>- 30 Hoehn &amp; Yahr stage III (moderate disease, balance issues)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Auditory Cueing</intervention_name>
    <description>Metronome beat to step in time with</description>
    <arm_group_label>Hoehn &amp; Yahr stage I (H&amp;YI)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage II (H&amp;YII)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage III (H&amp;YIII)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visual Cueing</intervention_name>
    <description>Lines on the floor to step over</description>
    <arm_group_label>Hoehn &amp; Yahr stage I (H&amp;YI)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage II (H&amp;YII)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage III (H&amp;YIII)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tactile Cueing</intervention_name>
    <description>Vibration to step in time with (metronome like)</description>
    <arm_group_label>Hoehn &amp; Yahr stage I (H&amp;YI)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage II (H&amp;YII)</arm_group_label>
    <arm_group_label>Hoehn &amp; Yahr stage III (H&amp;YIII)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will involve 80 participants with PD, who will be split into groups dependent on&#xD;
        the severity of their disease (classified with the Hoehn and Yahr (H&amp;Y) scale); n=20 H&amp;Y&#xD;
        stage I (early disease, minimal symptoms); n=30 H&amp;Y stage II (mild disease, no balance&#xD;
        issues); n=30 H&amp;Y stage III (moderate disease, balance issues).&#xD;
&#xD;
        Within the H&amp;Y stage II and III groups, we will also ensure recruitment of a sub-group of&#xD;
        n=15 individuals who self-report FOG within each group (n=30 total with FOG), which will&#xD;
        provide a sub-group for further data analysis. We will limit FOG sub-group recruitment to&#xD;
        these groups as we do not expect any individuals with FOG to be in H&amp;Y stage I.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Parkinson's by a movement disorder specialist according to&#xD;
             United Kingdom (UK) brain bank criteria&#xD;
&#xD;
          -  Hoehn &amp; Yahr (H&amp;Y) stage I-III&#xD;
&#xD;
          -  Aged &gt;50 years&#xD;
&#xD;
          -  Able to walk and stand unaided&#xD;
&#xD;
          -  Adequate hearing (as evaluated by the whisper test; stand 2m behind subject and&#xD;
             whisper a 2 syllable word, subject repeats word) and vision capabilities (as measured&#xD;
             using a Snellen chart - 6/18-6/12).&#xD;
&#xD;
          -  Stable medication for the past 1 month and anticipated over a period of 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric co-morbidity (e.g., major depressive disorder as determined by Geriatric&#xD;
             Depression Scale - short form (GDS-15); &lt;10 [26])&#xD;
&#xD;
          -  Clinical diagnosis of dementia or other severe cognitive impairment (Montreal&#xD;
             cognitive assessment &lt;21 [27])&#xD;
&#xD;
          -  History of stroke, traumatic brain injury or other neurological disorders (other than&#xD;
             PD, for the PD group)&#xD;
&#xD;
          -  Acute lower back or lower extremity pain, peripheral neuropathy, rheumatic and&#xD;
             orthopaedic diseases&#xD;
&#xD;
          -  Unstable medical condition including cardio-vascular instability in the past 6 months&#xD;
&#xD;
          -  Unable to comply with the testing protocol or currently participating in another&#xD;
             interfering research project&#xD;
&#xD;
          -  Interfering therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Stuart, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northumbria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Stuart, PhD</last_name>
    <phone>01912233343</phone>
    <email>sam.stuart@northumbria.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northumbria University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Stuart, PhD</last_name>
      <phone>01912233343</phone>
      <email>sam.stuart@northumbria.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Rosie Morris, PhD</last_name>
      <email>rosie.e.morris@northumbria.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Julia Das</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northumbria Healthcar NHS foundation trust</name>
      <address>
        <city>North Shields</city>
        <zip>NE29 8NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Walker</last_name>
      <phone>01912932709</phone>
      <email>richard.walker@northumbria-healthcare.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pi-lab.co.uk</url>
    <description>Physiotherapy Innovation Laboratory Website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkison's disease</keyword>
  <keyword>Gait</keyword>
  <keyword>functional near infrared spectroscopy</keyword>
  <keyword>electroencephalography</keyword>
  <keyword>Inertial Sensors</keyword>
  <keyword>Brain activity</keyword>
  <keyword>Cueing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to the datasets can be obtained by contacting the principle investigator.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT04863560/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

